Other research product . Other ORP type . 2018

Synthetic immune niches for cancer immunotherapy

Name: Synthetic immune niches for cancer immunotherapy
Keywords: Journal Article, Review, SDG 3 - Good Health and Well-being

Weiden, J.; Tel, J.; Figdor, C.G.;

Open Access

English

Published: 01 Mar 2018

- Summary
- References
  (21)

Abstract

Cancer immunotherapy can successfully promote long-term anticancer immune responses, although there is still only a limited number of patients who benefit from such treatment, and it can sometimes have severe treatment-associated adverse events. Compared with systemic immunomodulation, local immunomodulation may enable more effective treatment at lower doses and, at the same time, prevent systemic toxicity. Local delivery of engineered three-dimensional scaffolds may fulfil this role by acting as synthetic immune niches that boost anticancer immunity. In this Opinion article, we highlight the potential of scaffold-based adoptive cell transfer and scaffold-based cancer vaccines that, although applied locally, can promote systemic antitumour immunity. Furthermore, we discuss how scaffold-based cancer immunotherapy may contribute to the development of the next generation of cancer treatments.

Subjects

Journal Article, Review, SDG 3 - Good Health and Well-being

Related Organizations

STICHTING RADBOUD UNIVERSITEIT
Netherlands

21 references, page 1 of 3

Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363, 711-23 (2010).

Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372, 320-30 (2015).

Larkin, J. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373, 23-34 (2015).

Michot, J.M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54, 139-48 (2016).

Dudley, M.E. et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 31, 2152-9 (2013).

Stevanovic, S. et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 33, 1543-50 (2015).

Junker, N. et al. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. Cytotherapy 13, 822-34 (2011).

Ahmed, N. et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol 33, 1688-96 (2015).

Rosenberg, S.A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17, 4550-7 (2011).

Rosenberg, S.A. & Restifo, N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62-8 (2015). [OpenAIRE]

chevron_left
1
2
3
chevron_right

See an issue? Give us feedback

Funded by

EC| PATHFINDER, NWO| The Institute for Chemical Immunology ICI

Download from

lock_open

NARCIS

Other ORP type . 2018

Providers: NARCIS